Annual Report

Overview

The report presents FY2015 consolidated sales of ¥290,498 million, down 1.8%, while overseas self-medication sales grew 10.1% to ¥27.9 billion. It describes the Group's expansion in overseas markets and its prescription portfolio, including the recently launched diabetes agent Lusefi. Environmental disclosures include a company energy-intensity reduction goal and landfill disposal equal to 0.25% of total waste emissions.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014-2015
Period: 1 April 2014 – 31 March 2015
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services